Tagged with B

Goltsblat BLP Pepeliaev, Goltsblat & Partners and the major UK firm Berwin Leighton Paisner (BLP). It calls itself the first international Russian law firm. Can you explain to our readers the rationale behind the creation of this firm and why Goltsblat BLP is interesting for the market? There was a split amongst…

Galderma Laboratories Russia You were working for GSK since 2003 before joining Galderma this year. Some within the industry might view Galderma as a step down from the third-ranked pharmaceutical company in the world. What convinced you to take this position? I would certainly not call my transition to Galderma a step down!…

Ţuca Zbârcea & Asociaţii A lot of the opportunities and challenges in the pharma and healthcare sector of Romania depend on the overall Romanian business environment in the first place. How would you assess the overall attractiveness of the Romanian business environment for foreign companies? Romania’s overall business environment has improved significantly over the…

Boehringer Ingelheim Romania If we take a look back at Boehringer Ingelheim’s dynamic growth path in the Romanian market, we see an evolution from a one-man show in the 1990s to a present day subsidiary of over 100 people. What have been the key milestones and achievements for you since joining this subsidiary…

Biocodex Russia You have been at your current position for less than a year, and joined BIOCODEX after having managed the Russian affiliate of Yves Saint Laurent. You have a long history of working in the luxury goods industry, but no pharmaceutical management experience. How do you navigate the challenge of entering…

BOIRON Romania Records show that the field of homeopathy has a long history in Romania, dating back to the late 1800s. However, the real growth only really took off in the 1990s. Can you give a brief introduction on homeopathy in Romania and what have been some of the key milestones for…

Biopharmaceutical investments of RVC (RVC BioFund) Biofund is an independent spin-off of the broader Russian Venture Capital organization. What is the working relationship and synergy between these agencies, and what are the market conditions that have necessitated the creation of Biofund? Biofund was created on January 24th, 2011. There are two stakeholders in the creation of…

Serbia Serbia has had an undoubtedly troubled history since the breakup of Yugoslavia in the early 1990s. A costly war and ensuing UN sanctions have left the country’s economy a few years behind those of its regional counterparts. The subsequent global financial crisis in the late 2000s resulted in another hit…

Bayer UK/Ireland Within the global trend of increased economic pressures on the pharmaceutical industry, there has been a recent focus on growth in emerging markets. In this context, where does this leave mature markets, such as the UK and how do you aim to position the company locally? The UK is perceived…

Bayer Healthcare Pharmaceuticals Russia You were a Russian manager from 1996-2004, departed to Germany for some time, and recently made your way back to Russia in 2010. How has Russian healthcare and industry changed, and what do you find most striking? The biggest difference is the fact that the government is much more involved…

Pierre Fabre Russia You were responsible for merging Pierre Fabre’s activities in Russia in 2008, and heading the new legal entity and 100% subsidiary. What is it like to set up a new affiliate in Russia? What challenges did you face and how smooth did you find the process? We faced two significant…

Baker & McKenzie Russia Baker & McKenzie differentiates itself from competitors by offering an industry-focused practice. Has this model continued to give this company a leading edge in Russia, and, overall, what is your assessment of this firm’s positioning on the Russian market today? I would say yes, this has differentiated us from competitors.…